.jpeg)
2026-09-10 03:00:52
Worsening symptoms or declining cardiac function during acoramidis treatment for ATTR-CM should not be directly labeled as drug resistance. This article explains the mechanism, proper assessment methods, and dosing compliance.
2026-09-10 02:56:36
Lorlatinib has only one formal contraindication (prohibited co-administration with strong CYP3A inducers), but six major safety risks require close attention, including CNS effects, dyslipidemia, and interstitial lung disease.
2026-09-09 07:04:37
Dacomitinib is a second-generation irreversible EGFR TKI for first-line treatment of metastatic NSCLC with EGFR exon 19 deletion or L858R mutation. This article details dosing, switching strategies, comparison with osimertinib, and adverse event management.
2026-09-09 06:37:44
Abemaciclib is a CDK4/6 inhibitor for hormone receptor-positive, HER2-negative breast cancer. This article explains its mechanism, synergy with endocrine therapy, efficacy differences between mono and combination, and precautions when switching from other CDK4/6 inhibitors.
2026-09-08 05:30:58
Cemiplimab is a PD-1 immune checkpoint inhibitor that blocks PD-1 from binding to PD-L1/PD-L2, releasing T-cell suppression and enabling immune attack on tumors. This article explains its mechanism and clinical indication screening.
2026-09-07 07:24:27
Tivozanib (FOTIVDA) is an oral targeted therapy for renal cell carcinoma, given on a 21-day-on, 7-day-off schedule. This article details standard dosing, hepatic impairment adjustment, hypertension monitoring, and side effect management.
2026-09-01 04:42:07
Selpercatinib is an oral RET inhibitor for RET fusion–positive NSCLC, thyroid cancer and other solid tumors, and RET-mutant medullary thyroid cancer. Dosing is weight-based, and acid-reducing agents require attention.
2026-09-01 03:28:25
Alpelisib is an oral PI3Kα inhibitor marketed as Piqray with fulvestrant for PIK3CA-mutated HR+/HER2− advanced breast cancer, and as Vijoice for PIK3CA-related overgrowth spectrum (PROS).
2026-08-31 03:59:58
Capmatinib is a highly selective MET inhibitor for metastatic NSCLC harboring MET exon 14 skipping mutations, with efficacy established by the GEOMETRY mono-1 trial in both first-line and previously treated settings.
2026-08-31 03:37:12
The combination is approved for first-line treatment of locally advanced or metastatic NSCLC harboring EGFR exon 19 deletions or exon 21 L858R substitutions, with PFS and OS advantages over osimertinib in MARIPOSA.
2026-08-31 03:26:31
Lapatinib is an oral reversible dual EGFR/HER2 tyrosine kinase inhibitor used in previously treated HER2-positive advanced or metastatic breast cancer to delay disease progression.
2026-08-27 07:05:19
Mirdametinib is a MEK1/2 inhibitor approved by the FDA for symptomatic, inoperable plexiform neurofibromas in patients with NF1 aged 2 years and older. This article explains its mechanism, ReNeu trial data, and targeted therapy value.
